Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Phase III Trial

  • Home
  • Phase III Trial
Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial
Posted innews Oncology

Eryaspase Fails to Improve Survival in Second‑Line Advanced Pancreatic Cancer: Results from the Phase III TRYBECA‑1 Trial

Posted by MedXY By MedXY 12/08/2025
In TRYBECA‑1, adding erythrocyte‑encapsulated L‑asparaginase (eryaspase) to second‑line chemotherapy did not improve overall survival, progression‑free survival, or response rates in advanced pancreatic ductal adenocarcinoma; adverse events were modestly increased.
Read More
Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial
Posted inClinical Updates news Oncology Specialties

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

Posted by MedXY By MedXY 09/08/2025
The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.
Read More
  • Reassessing Diagnostic Tools for Peripheral Arterial Disease in Diabetes: Insights from the DMPAD Study
  • Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial
  • JCAD Protein: A Novel Predictor and Therapeutic Target for Residual Cardiovascular Risk in Acute Coronary Syndrome
  • Navigating Uncertainty: Rapid Evidence Generation and Translation of Anticoagulation Strategies in Noncritically Ill COVID-19 Patients
  • Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in